ReviewFrontiers in immunology2021
Potential Role of the Gut Microbiome In Colorectal Cancer Progression.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 6 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Impact of Gut Microbiota on the Clinical Course and Treatment Outcomes of Colorectal Cancer-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Gut microbiome biomarkers for colorectal cancer detection: a systematic review highlighting age as a key confounder.Frontiers in oncology · 2026Pooled it
- The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).Oncology research · 2026Pooled it
- Meta-analysis of gut microbiome reveals patterns of dysbiosis in colorectal cancer patients.Journal of medical microbiology · 2025Pooled it
- Prevalence of enterotoxigenicFrontiers in cellular and infection microbiology · 2025Pooled it
- Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential.Molecular biomedicine · 2026Review
- MIF Deficiency Modulates Gut Microbiota Composition and Promotes Colitis-Associated Colorectal Cancer in a Murine Model.Current issues in molecular biology · 2026Article
- Exploratory analysis of genotoxic Escherichia coli and Helicobacter pylori virulence in gastrointestinal carcinogenesis.AMB Express · 2026Article
- Atractylodes macrocephala polysaccharide orchestrates anti-tumor immunity via a dual-network mechanism targeting the gut microbiota and spleen.NPJ biofilms and microbiomes · 2026Article
- Features of the Intestinal and Respiratory Microbiome in Colorectal Cancer Patients in Western Siberia.Microorganisms · 2026Article
- The Phylum Fusobacteriota Is Associated with Colorectal Cancer-Specific Mortality: Results from the Translational Research Program in Cancer Differences across Populations.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Unveiling the Molecular Repertoire ofJournal of microbiology and biotechnology · 2026Review
- Article
- Inflammatory Stromal Aging in Ulcerative Colitis and Colitis-Associated Cancer.bioRxiv : the preprint server for biology · 2026Article
- Mapping of Phenotype Specific Host-Microbiome Protein-Protein Interaction Networks in Colorectal Cancer Using Deep Learning.International journal of molecular sciences · 2026Article
- Article
- Association between socio-economic status and intestinal microbiota composition in patients with colorectal adenomas.Scientific reports · 2026Article
- Modeling Microbiome Modulation of Tumor Metabolic Networks to Predict Synergistic Therapies.bioRxiv : the preprint server for biology · 2026Article
- Chronic Antibiotic Use, Gut Microbiota Dysbiosis, and Increased Risk of Colorectal Cancer: An Emerging Threat.Health science reports · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of studies have revealed that the progression of colorectal cancer (CRC) is related to gut microbiome composition. Under normal conditions, the gut microbiome acts as a barrier to other pathogens or infections in the intestine and modulates inflammation by affecting the host immune system. These gut microbiota are not only related to the intestinal inflammation associated with tumorigenesis but also modulation of the anti-cancer immune response. Thus, they are associated with tumor progression and anti-cancer treatment efficacy. Studies have shown that the gut microbiota can be used as biomarkers to predict the effect of immunotherapy and improve the efficacy of immunotherapy in treating CRC through modulation. In this review, we discuss the role of the gut microbiome as revealed by recent studies of the growth and progression of CRC along with its synergistic effect with anti-cancer treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.